Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer.

Por Meazza, R., Marciano, S., Sforzini, S., Orengo, A. M., Coppolecchia, M., Musiani, P., Ardizzoni, A., Santi, L., Azzarone, B., Ferrini, S.
Publicado em 1996

Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)

Por Baldini, E, Ardizzoni, A, Prochilo, T, Cafferata, M A, Boni, L, Tibaldi, C, Neumaier, C, Conte, P F, Rosso, R
Publicado em 2001

PTEN status in advanced colorectal cancer treated with cetuximab

Por Negri, F V, Bozzetti, C, Lagrasta, C A, Crafa, P, Bonasoni, M P, Camisa, R, Pedrazzi, G, Ardizzoni, A
Publicado em 2010

Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimi...

Por Ardizzoni, A., Pennucci, M. C., Danova, M., Viscoli, C., Mariani, G. L., Giorgi, G., Venturini, M., Mereu, C., Scolaro, T., Rosso, R.
Publicado em 1996

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer

Por Ardizzoni, A, Grossi, F, Scolaro, T, Giudici, S, Foppiano, F, Boni, L, Tixi, L, Cosso, M, Mereu, C, Ratto, G Battista, Vitale, V, Rosso, R
Publicado em 1999

Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast c...

Por Ardizzoni, A., Venturini, M., Sertoli, M. R., Giannessi, P. G., Brema, F., Danova, M., Testore, F., Mariani, G. L., Pennucci, M. C., Queirolo, P.
Publicado em 1994

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Canc...

Por Ardizzoni, A., Addamo, G. F., Baldini, E., Borghini, U., Portalone, L., De Marinis, F., Lionetto, R., Conte, P. F., Bruzzi, P., Pennucci, M. C.
Publicado em 1995

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR...

Por Cascinu, S, Berardi, R, Salvagni, S, Beretta, G D, Catalano, V, Pucci, F, Sobrero, A, Tagliaferri, P, Labianca, R, Scartozzi, M, Crocicchio, F, Mari, E, Ardizzoni, A
Publicado em 2008

Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy

Por Negri, F V, Campanini, N, Camisa, R, Pucci, F, Bui, S, Ceccon, G, Martinelli, R, Fumagalli, M, Losardo, P L, Crafa, P, Bordi, C, Cascinu, S, Ardizzoni, A
Publicado em 2008

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Por Bozzetti, C, Negri, F V, Lagrasta, C A, Crafa, P, Bassano, C, Tamagnini, I, Gardini, G, Nizzoli, R, Leonardi, F, Gasparro, D, Camisa, R, Cavalli, S, Silini, E M, Ardizzoni, A
Publicado em 2011

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Por Bozzetti, C, Negri, F V, Lagrasta, C A, Crafa, P, Bassano, C, Tamagnini, I, Gardini, G, Nizzoli, R, Leonardi, F, Gasparro, D, Camisa, R, Capelli, S, Silini, E M, Ardizzoni, A
Publicado em 2011

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

Por Tiseo, M, Bordi, P, Bortesi, B, Boni, L, Boni, C, Baldini, E, Grossi, F, Recchia, F, Zanelli, F, Fontanini, G, Naldi, N, Campanini, N, Azzoni, C, Bordi, C, Ardizzoni, A
Publicado em 2013

P-027 Cancer stem cells marker CD44 and Notch activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapy

Por Negri, F.V., Bozzetti, C., Azzoni, C., Bottarelli, L., Squadrilli, A., Pedrazzi, G., Lagrasta, C., Tamagnini, I., Bisagni, A., Porzio, R., Tomasello, G., Leonardi, F., Pinto, C., Ardizzoni, A., Sala, R., Quaini, F.
Publicado no Ann Oncol (2016)

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial tr...

Por Boni, C, Tiseo, M, Boni, L, Baldini, E, Recchia, F, Barone, C, Grossi, F, Germano, D, Matano, E, Marini, G, Labianca, R, Di Costanzo, F, Bagnulo, A, Pennucci, C, Caroti, C, Mencoboni, M, Zanelli, F, Prochilo, T, Cafferata, M A, Ardizzoni, A
Publicado em 2012

Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONIC...

Por Baldini, E., Tibaldi, C., Ardizzoni, A., Salvati, F., Antilli, A., Portalone, L., Barbera, S., Romano, F., De Marinis, F., Migliorino, M. R., Noseda, M. A., Borghini, U., Crippa, M., Ferrara, G., Raimondi, M., Fioretti, M., Bandera, M., Pennucci, M. C., Galeasso, G., Cacciani, G. C., Lepidini, G., Sunseri, G., Lanfranco, C., Rinaldi, M., Rosso, R.
Publicado em 1998